BioNano Genomics (BNGO) AI Stock Analysis

• Market Cap: $17.04M
• Dividend Yield: N/A
• Average Volume (3M): 137.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.34
• Revenue Growth: -25.02%
• EPS Growth: 85.08%
• Country: US
• Employees: 98
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -1.99
• Shares Outstanding: 4,681,000
• 10 Day Avg. Volume: 217,594
• 30 Day Avg. Volume: 137,765
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.20
• Enterprise Value/Revenue: 0.12
• Enterprise Value/Gross Profit: 2.47
• Enterprise Value/Ebitda: -0.05
• 1Y Price Target: $7.67
• Price Target Upside: 92.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 50 Neutral
• Price Target: $4.00 ▲(0.25% Upside)

BioNano Genomics' overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and profitability challenges. While technical analysis shows some short-term strength, the valuation remains unattractive due to negative earnings. The earnings call provides a cautiously optimistic outlook with strategic advancements, but significant risks remain.

Positive Factors

Market Position

Bionano shares are currently trading at an EV/Revenue multiple of 0.2x, which is less than one tenth of comparable companies’ average multiple of 3.5x.

Regulatory Approval

The editorial panel of the American Medical Association (AMA) established a second Category I Current Procedural Terminology (CPT) code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations relative to constitutional genetic disorders.

Technology Advancements

New versions of VIA and Solve software enhance capabilities, part of Bionano's strategy to broaden its utilization by enhancing software capabilities that streamline data reporting and analysis for OGM.

Negative Factors

Market Challenges

Bionano reduced its 2025 revenue guidance, reflecting challenges in the U.S. life science space.

Revenue Decline

Total revenue was $6.7M, representing 13% YoY decline and missing our projection of $7.4M.

Revenue Guidance

Bionano's full year revenue guidance of $26M-$30M is lower than the previous year's $30.8M, indicating a cautious outlook.

BioNano Genomics Business Overview & Revenue Model

Company Description

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

How the Company Makes Money

BioNano Genomics generates revenue primarily through the sale of its Saphyr systems, along with consumables and software licenses associated with its genomic analysis technology. The company has established key partnerships with academic institutions, research organizations, and clinical laboratories, which contribute to its revenue through collaborations and joint research initiatives. Additionally, BNGO may benefit from licensing agreements and collaborations with pharmaceutical companies looking to leverage its technology for drug development and precision medicine applications. The diverse applications of its optical genome mapping technology across various research and clinical settings enhance its potential revenue streams.

BioNano Genomics Financial Statement Overview

Summary

BioNano Genomics faces significant financial challenges, with declining revenues, negative profitability, and cash flow inefficiencies. While there is some improvement in leverage, the company struggles to generate positive returns and cash flows, posing risks to financial stability.

Income Statement

BioNano Genomics has experienced declining revenue growth, with a negative growth rate in the TTM period. The company shows weak profitability, with consistently negative net profit margins and EBIT margins. Gross profit margins are low, indicating challenges in cost management.

Balance Sheet

The company's debt-to-equity ratio has improved in the TTM period, suggesting better leverage management. However, the return on equity remains negative, indicating continued losses. The equity ratio is relatively stable, but the company faces challenges in generating returns for shareholders.

Cash Flow

BioNano Genomics shows negative free cash flow growth in the TTM period, reflecting cash flow challenges. The operating cash flow to net income ratio is negative, indicating inefficiencies in converting income to cash. The free cash flow to net income ratio is slightly above 1, showing some consistency in cash flow relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	27.43M	30.78M	36.12M	27.80M	17.98M	8.50M
Gross Profit	1.39M	380.00K	9.57M	5.95M	3.87M	2.77M
EBITDA	-68.93M	-97.47M	-213.60M	-120.31M	-73.86M	-37.08M
Net Income	-74.33M	-112.02M	-232.49M	-132.60M	-72.44M	-41.14M
Balance Sheet
Total Assets	76.01M	76.67M	214.40M	307.50M	377.10M	60.45M
Cash, Cash Equivalents and Short-Term Investments	16.44M	9.47M	66.77M	113.19M	250.61M	38.45M
Total Debt	19.58M	27.30M	79.41M	11.67M	10.70M	16.33M
Total Liabilities	30.64M	41.30M	118.25M	58.10M	39.98M	25.37M
Stockholders Equity	45.37M	35.38M	96.16M	249.40M	337.12M	35.08M
Cash Flow
Free Cash Flow	-26.06M	-69.03M	-126.87M	-128.12M	-73.39M	-38.31M
Operating Cash Flow	-26.06M	-68.92M	-125.18M	-124.82M	-71.93M	-38.31M
Investing Cash Flow	-14.46M	73.84M	24.16M	82.77M	-278.06M	-2.45M
Financing Cash Flow	22.27M	-13.69M	113.81M	23.01M	336.11M	61.90M

BioNano Genomics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.99
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNGO, the sentiment is Positive. The current price of 3.99 is above the 20-day moving average (MA) of 3.58, above the 50-day MA of 3.40, and below the 200-day MA of 6.08, indicating a neutral trend. The MACD of 0.18 indicates Negative momentum. The RSI at 59.47 is Neutral, neither overbought nor oversold. The STOCH value of 36.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BNGO.

BioNano Genomics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ENZB	54 Neutral	$36.59M	―	-13.95%	―	―	―
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
BNR	51 Neutral	$90.93M	―	-37.15%	―	-0.26%	60.09%
BNGO	50 Neutral	$17.04M	―	-118.26%	―	-25.02%	85.08%
INBS	48 Neutral	$13.65M	―	-186.64%	―	-1.90%	87.72%
MYNZ	44 Neutral	$7.69M	―	-809.29%	―	―	―
BIAF	44 Neutral	$6.81M	―	-1802.45%	―	4.99%	22.58%

BioNano Genomics Corporate Events

BioNano Genomics Enhances Governance with New Appointment

On June 10, 2025, BioNano Genomics appointed Kristiina Vuori, M.D., Ph.D., to its Audit Committee, enhancing its governance structure. During the company’s 2025 Annual Meeting of Stockholders on June 11, 2025, key decisions included the election of Class I Directors, approval of executive compensation, ratification of BDO USA, P.C. as the independent accounting firm, and approval of the issuance of shares upon exercise of purchase warrants, reflecting active shareholder engagement and strategic alignment with Nasdaq requirements.